English-arkiv - Page 8 of 25

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023

GOTHENBURG, Sweden, April 16, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report […]

Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)

GOTHENBURG, Sweden, April 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration

Isofol presents a clinical development plan for arfolitixorin

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today presents the company’s continued strategy

Isofol invites to investor meeting on March 19

GOTHENBURG, Sweden, March 1, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors and shareholders to an

Isofol Medical AB (publ) publishes year-end report, January – December 2023

GOTHENBURG, Sweden, February 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report

Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19

GOTHENBURG, Sweden, February 14, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), has been engaged in intensive strategy work

English